
|Articles|May 1, 2007
Bevacizumab appears safe for neovascular AMD in short term
The short-term clinical experience with intravitreal bevacizumab (Avastin, Genentech) supports growing perception that treatment is safe and effective for neovascular age-related macular degeneration.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema
2
The Residency Report: Cardiovascular risk scores as a window into ocular disease
3
TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis
4
FDA guidance to help accelerate cell and gene therapies
5





















